Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households

Journal of Infectious Diseases

Volumn 186, Issue 11, 2002, Pages 1582-1588

  Monto, Arnold S ^a   Pichichero, Michael E ^b   Blanckenberg, Steve J ^c   Ruuskanen, Olli ^d   Cooper, Chris ^e   Fleming, Douglas M ^f   Kerr, Caron ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Jan Hofmeyr Road Practice ^*  (South Africa)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Northfield Health Center   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DEXTROMETHORPHAN; INFLUENZA VACCINE; OSELTAMIVIR; PARACETAMOL; PLACEBO; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CHEMOPROPHYLAXIS; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOUSEHOLD; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION; DOUBLE-BLIND METHOD; FAMILY CHARACTERISTICS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MICROBIAL SENSITIVITY TESTS; PYRANS; SIALIC ACIDS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 0036891408     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345722     Document Type: Article

References (30)

1. Fox JP, Hall CE, Cooney MK, Foy HM. Influenza virus infections in Seattle families, 1975-1979. Am J Epidemiol 1982; 116:212-42.
2. Longini IM, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982; 115:736-51.
3. Centers For Disease Control and Prevention. Prevention and Control of Influenza: Recommendations of the Immunization Practices Advisory Committee (ACIP). Available at: http://www.cdc.gov/nip/ACIP.
4. Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantadine hydrochloride on influenza A2 infections in the family environment: A controlled double-blind study. Lancet 1969; 2:1026-8.
5. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
6. Tisdale M. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors. Rev Med Virol 2000; 10:45-55.
7. Hayden FH, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343:1282-9.
8. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial. JAMA 2001; 285:748-54.
9. Belshe RB, Hayden F, Carewicz O, et al. Effectiveness of oral oseltamivir in preventing spread of influenza-like illness in households with proven influenza [abstract 663]. In: Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2002:289.
10. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337:874-80.
11. MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352:1877-81.
12. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:254-61.
13. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study. J Infect 2000; 40:42-8.
14. Hedrick JA, Barzilai A, Behre U. et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial. Pediatr Infect Dis J 2000; 19:410-7.
15. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA 1999; 282:31-5.
16. World Medical Association Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 227:925-6.
17. Zambon M. Laboratory diagnosis of influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science, 1998:291-313.
18. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000; 44:78-87.
19. Gart J. Point and interval estimation of the common odds ratio in the combination of 2x2 tables with fixed marginals. Biometrika 1970; 57:471-5.
20. Cox DR. A simple example of a comparison involving quantal data. Biometrika 1966; 53:215-20.
21. Cox DR. The Analysis of Binary Data. London: Methuen, 1970.
22. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and agents involved. Epidemiol Infect 1993; 110:145-60.
23. Treanor JJ, Hayden FG, Vrooman, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283:1016-24.
24. Hayden FG, Gwaltney JM Jr, van de Castle RL, Adams KF, Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981; 19:266-33.
25. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetral). J Am Geriatr Soc 1975; 23:212-5.
26. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224-8.
27. Kaiser L, Keene ON. Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
28. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: A pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161:212-7.
29. Nicholson KG, Snacken R, Palache AM. Influenza immunization policies in Europe and the United States. Vaccine 1995; 13:365-9.
30. Webster A, Boyce M, Edmundson S, Miller I. Co-administration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutanin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36(Suppl 1):51-8.